We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Infinity Pharma Focuses on Cancer Drug: Competition Looms
Read MoreHide Full Article
We issued an updated research report on Infinity Pharmaceuticals, Inc. on Mar 20, 2017.
Infinity’s share price has increased considerably by 148.9% year to date, while the Zacks classified Medical-Drugs industry gained 4.7%.
The company is currently focused on the development of its lead immuno-oncology candidate, IPI-549. It is an orally administered treatment that selectively inhibits phosphoinositide-3 kinase (PI3K)-gamma. Infinity entered into clinical trial collaboration with Bristol-Myers Squibb (BMY - Free Report) to evaluate IPI-549 in combination with the latter’s checkpoint inhibitor Opdivo in patients with advanced solid tumors.
While the dose-escalation portion of the phase I study evaluating the activity, safety, tolerability, pharmacokinetics and pharmacodynamics of IPI-549 as monotherapy is expected to be completed in the first half of 2017, the monotherapy expansion phase in patients with advanced solid tumors is anticipated to begin in the second half of the year.
The company also expects to complete the dose-escalation phase evaluating IPI-549 in combination with Opdivo in the second half of 2017. In fact, Infinity Pharma’s progress with the candidate has been impressive. Moreover, clinical trial collaboration with Bristol-Myers has provided Infinity with a strong partner with expertise in the field of immuno-oncology. Further, it would allow Infinity to expedite the development of IPI-549.
Once the dose-escalation phase on the combination is complete, an expansion phase will evaluate the combination in patients with selected solid tumors, including non-small cell lung cancer (NSCLC), melanoma and squamous cell carcinoma of the head and neck (SCCHN) in the second half of 2017. IPI-549 represents a potentially complementary approach to restoring anti-tumor immunity in combination with other immunotherapies such as checkpoint inhibitors. If successfully developed, approval of IPI-549 will be a huge boost for Infinity.
In Oct 2016, Infinity Pharma entered into a license agreement with Verastem, under which it granted exclusive worldwide rights to develop and commercialize its oncology candidate duvelisib to the latter. The agreement will see Infinity receiving up to $28 million across two milestone payments Infinity is also eligible to receive tiered mid-to-high single-digit royalties on net sales of duvelisib, subject to approval We are positive on the deal, which will provide Infinity with much needed funds.
However, Infinity has no approved product in its portfolio at the moment, with only IPI-549 in the pipeline. The company is thus totally dependent on the candidate for growth.
Infinity faces stiff competition in the fields of immuno-oncology from companies like AstraZeneca Plc (AZN - Free Report) , Celgene Corp. , Merck, Novartis, Pfizer, Roche and Eli Lilly among others.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think. See This Ticker Free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Infinity Pharma Focuses on Cancer Drug: Competition Looms
We issued an updated research report on Infinity Pharmaceuticals, Inc. on Mar 20, 2017.
Infinity’s share price has increased considerably by 148.9% year to date, while the Zacks classified Medical-Drugs industry gained 4.7%.
The company is currently focused on the development of its lead immuno-oncology candidate, IPI-549. It is an orally administered treatment that selectively inhibits phosphoinositide-3 kinase (PI3K)-gamma. Infinity entered into clinical trial collaboration with Bristol-Myers Squibb (BMY - Free Report) to evaluate IPI-549 in combination with the latter’s checkpoint inhibitor Opdivo in patients with advanced solid tumors.
While the dose-escalation portion of the phase I study evaluating the activity, safety, tolerability, pharmacokinetics and pharmacodynamics of IPI-549 as monotherapy is expected to be completed in the first half of 2017, the monotherapy expansion phase in patients with advanced solid tumors is anticipated to begin in the second half of the year.
The company also expects to complete the dose-escalation phase evaluating IPI-549 in combination with Opdivo in the second half of 2017. In fact, Infinity Pharma’s progress with the candidate has been impressive. Moreover, clinical trial collaboration with Bristol-Myers has provided Infinity with a strong partner with expertise in the field of immuno-oncology. Further, it would allow Infinity to expedite the development of IPI-549.
Once the dose-escalation phase on the combination is complete, an expansion phase will evaluate the combination in patients with selected solid tumors, including non-small cell lung cancer (NSCLC), melanoma and squamous cell carcinoma of the head and neck (SCCHN) in the second half of 2017. IPI-549 represents a potentially complementary approach to restoring anti-tumor immunity in combination with other immunotherapies such as checkpoint inhibitors. If successfully developed, approval of IPI-549 will be a huge boost for Infinity.
In Oct 2016, Infinity Pharma entered into a license agreement with Verastem, under which it granted exclusive worldwide rights to develop and commercialize its oncology candidate duvelisib to the latter. The agreement will see Infinity receiving up to $28 million across two milestone payments Infinity is also eligible to receive tiered mid-to-high single-digit royalties on net sales of duvelisib, subject to approval We are positive on the deal, which will provide Infinity with much needed funds.
However, Infinity has no approved product in its portfolio at the moment, with only IPI-549 in the pipeline. The company is thus totally dependent on the candidate for growth.
Infinity faces stiff competition in the fields of immuno-oncology from companies like AstraZeneca Plc (AZN - Free Report) , Celgene Corp. , Merck, Novartis, Pfizer, Roche and Eli Lilly among others.
Infinity Pharmaceuticals, Inc. Price
Infinity Pharmaceuticals, Inc. Price | Infinity Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Infinity Pharma is a Zacks Rank #1 (Strong Buy) stock. You can see the complete list of today’s Zacks #1 Rank stocks here
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think. See This Ticker Free >>